atrial fibrillation, ventricular arrhythmias, myocardial fibrosis, myocardial scar
Conditions
Interventions
Late enhancement imaging using photon-counting detector CT.
Sponsors
Maastricht Universitair Medisch Centrum +
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria:Age between 18-80 years oldClinical indicated to undergo a first AF ablation (n=20) or re-do (hybrid) AF ablation (n=20)Able and willing to provide written informed consentIn order to be eligible to participate in this study, a subject must meet all of the following criteria:Age between 18-80 years oldClinical indicated to undergo VA ablationAble and willing to provide written informed consent
Exclusion criteria
Exclusion criteria: Patients with impaired renal failure (estimated Glomerular Filtration Rate (eGFR) <30 mL/min/1,73m2)Patients with known moderate to severe allergy to contrast agentsPatients who are pregnant or breast-feedingPatients with a contra-indication for CMR:ClaustrophobiaBody weight >130 kg or BMI >35 or body habitus that does not fit into the gantryPatients who are considered not eligible (by treating physician)Logistically unfeasible to organize PCD-CT and/or CMR scan
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the detection of myocardial scar using PCD-CT LE in patients undergoing cardiac ablation therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives for all groups:To compare the presence, distribution and extent of myocardial edema and/or scar between LE PCD-CT imaging, LE CMR, and EAM.To assess changes in myocardial tissue before and after ablation procedures as visualized with LE PCD-CT To determine whether the distribution and extent of myocardial edema and/or scar detected by LE PCD-CT correlate with the success of the ablation procedure, defined as freedom from documented recurrence of atrial or ventricular arrhythmia at 12 months follow-up. Secondary objectives for group 1 (atrial fibrillation):To investigate the effect of AF ablation procedure on the left atrial substrate by determining anatomical, hemodynamic, and functional changes as visualized by 4D flow CMR and atrial strain measurements. To explore the association between 4D flow CMR-derived anatomical, hemodynamic, and functional parameters and long-term clinical outcomes following AF ablation. To assess the feasibility of differentiating between epicardial adipose tissue and myocardial fibrosis with LE PCD-CT. Secondary objectives for group 2 (ventricular arrhythmias): To evaluate ECV measurements obtained through PCD-CT with those obtained through CMR imaging.To assess changes in ECV by comparing pre- and post-ablation PCD-CT-derived values. | — |
Countries
Netherlands
Contacts
Public ContactMDK Lemmens
Maastricht Universitair Medisch Centrum +
Outcome results
None listed